Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Inflammatory Bowel Diseases

  Free Subscription

Articles published in Drugs

Retrieve available abstracts of 15 articles:
HTML format

Single Articles

    September 2023
    Ritlecitinib: First Approval.
    Drugs. 2023;83:1315-1321.
    PubMed     Abstract available

    July 2023
  2. GISBERT JP, Chaparro M
    Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
    Drugs. 2023 Jul 28. doi: 10.1007/s40265-023-01916.
    PubMed     Abstract available

  3. VUYYURU SK, Shackelton LM, Hanzel J, Ma C, et al
    Targeting IL-23 for IBD: Rationale and Progress to Date.
    Drugs. 2023;83:873-891.
    PubMed     Abstract available

  4. KEAM SJ
    Mirikizumab: First Approval.
    Drugs. 2023;83:1045-1052.
    PubMed     Abstract available

    May 2023
  5. SKJELLERUDSVEEN BM, Skoie IM, Dalen I, Grimstad T, et al
    The Effect of Biological Treatment on Fatigue in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Drugs. 2023 May 23. doi: 10.1007/s40265-023-01888.
    PubMed     Abstract available

    March 2023
  6. NUNEZ P, Quera R, Yarur AJ
    Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
    Drugs. 2023;83:299-314.
    PubMed     Abstract available

    November 2022
  7. HOY SM
    Deucravacitinib: First Approval.
    Drugs. 2022;82:1671-1679.
    PubMed     Abstract available

    September 2022
  8. PAIK J
    Correction to: Ozanimod: A Review in Ulcerative Colitis.
    Drugs. 2022 Sep 1. pii: 10.1007/s40265-022-01772.

    August 2022
  9. PAIK J
    Ozanimod: A Review in Ulcerative Colitis.
    Drugs. 2022 Aug 22. pii: 10.1007/s40265-022-01762.
    PubMed     Abstract available

    July 2022
  10. CRISPINO F, Grova M, Bruno EM, Monachino N, et al
    Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets.
    Drugs. 2022 Jul 28. pii: 10.1007/s40265-022-01750.
    PubMed     Abstract available

    June 2022
    Carotegrast Methyl: First Approval.
    Drugs. 2022;82:1011-1016.
    PubMed     Abstract available

    August 2021
  12. HANZEL J, Ma C, Vande Casteele N, Khanna R, et al
    Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Drugs. 2021 Aug 28. pii: 10.1007/s40265-021-01596.

    January 2021
  13. HANZEL J, Ma C, Casteele NV, Khanna R, et al
    Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Drugs. 2021 Jan 5. pii: 10.1007/s40265-020-01460.
    PubMed     Abstract available

    March 2020
  14. VUITTON L, Peyrin-Biroulet L
    Pharmacological Prevention of Postoperative Recurrence in Crohn's Disease.
    Drugs. 2020;80:385-399.
    PubMed     Abstract available

    February 2020
  15. KIM H, Alten R, Avedano L, Dignass A, et al
    The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
    Drugs. 2020;80:99-113.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.